David S. Dickens

The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia

Ghayas C. Issa, Ibrahim Aldoss, John F. DiPersio et al. · Nature · 2023 · 468 citations · Full text

Medicine, Molecular Biology, Oncology +13

Nonadherence to Oral Mercaptopurine and Risk of Relapse in Hispanic and Non-Hispanic White Children With Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group

Smita Bhatia, Wendy Landier, Muyun Shangguan et al. · Journal of Clinical Oncology · 2012 · 333 citations · Full text

Medicine, Oncology, Pharmacotherapy +11

6MP adherence in a multiracial cohort of children with acute lymphoblastic leukemia: a Children's Oncology Group study

Wendy Landier, Lindsey Hageman, Heeyoung Kim et al. · Blood · 2014 · 204 citations · Full text

Medicine, Oncology, Pediatrics +13

Menin Inhibition With Revumenib for <i>KMT2A</i> -Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101)

Ghayas C. Issa, Ibrahim Aldoss, Michael J. Thirman et al. · Journal of Clinical Oncology · 2024 · 184 citations · Full text

Medicine, Oncology, Pharmacology +12

Etanercept in the treatment of macrophage activation syndrome.

S Prahalad, Kevin E. Bove, David S. Dickens et al. · PubMed · 2001 · 142 citations

Life Sciences, Immunology, Pharmacotherapy +17